Monthly Archives: October 2019

SunGen Pharma Receives Eighth ANDA Approval from US FDA

PRINCETON, N.J., Oct. 31, 2019 (GLOBE NEWSWIRE) — SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it has received its eighth ANDA approval from the US Food and Drug… Read More

British American Tobacco Selects Synchronoss Digital Experience Platform to Speed Delivery of Highly Optimized Customer Journeys

New pilot project spans three European countries to support in-store sales team members BRIDGEWATER, N.J., Oct. 31, 2019 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ:SNCR), a global leader and innovator of cloud, messaging, digital and IoT products, today announced that… Read More

K2 Expands Footprint in Asia-Pacific Region with Acquisition of Australian Distributor

Low-code application development company to expand presence in Australia to meet increasing demand for cloud-based process automation solutions BELLEVUE, Wash., Oct. 31, 2019 (GLOBE NEWSWIRE) — SourceCode Technology Holdings, Inc. (“K2”), a leader in enterprise low-code application development, today announced… Read More

Bombardier Reports Third Quarter 2019 Results

Consolidated revenues of $3.7 billion, representing 8% organic growth(1) Consolidated adjusted EBITDA(2) and adjusted EBIT(2) of $255 million and $159 million, respectively; $143 million of reported EBIT Free cash flow usage(2) of $682 million, supporting Global 7500 and Transportation ramp-up;… Read More

Bombardier Announces Definitive Agreement to Sell Aerostructures Business to Spirit AeroSystems Holding, Inc.

Sale of aerostructures business supports Aviation transformation, refocuses on business aviation and strengthens liquidity Expected cash proceeds of $500 million (1) plus the assumptions of liabilities Transaction implies enterprise value to 2019E EBITDA multiple of approximately 10x  All amounts in… Read More

Ingredion Incorporated Reports Third Quarter 2019 Results

Third quarter 2019 reported and adjusted EPS* were $1.47 and $1.82, respectively, compared with $1.32 and $1.70 in the third quarter 2018, respectively Year-to-date 2019 reported and adjusted EPS were $4.51 and $5.03, respectively, down from $4.80 of reported EPS… Read More

Sanofi Q3 well on track

Paris, October 31, 2019 Sanofi Q3 well on track   Q3 2019 Change Change at CER 9M 2019 Change Change at CER IFRS net sales reported €9,499m +1.1% -1.1% €26,518m +4.1% +2.2% IFRS net income reported €1,766m -22.3% – €2,816m -30.5%(2)… Read More